Monitor for completion of the NDA submission in Q2 2026 and potential FDA acceptance for review, which could drive sentiment. However, with no near-term revenue catalyst and ongoing R&D costs, the stock reaction may be muted absent further clinical or regulatory developments.
Price Chart
Executive Summary
Belite Bio announced the initiation of a rolling NDA submission to the FDA for tinlarebant, a potential treatment for Stargardt disease type 1, supported by Phase 3 DRAGON trial data. The company expects to complete the submission in Q2 2026.
Key Financial Metrics
Key Facts
- Belite Bio initiated a rolling NDA submission to the FDA for tinlarebant for the treatment of Stargardt disease type 1 (STGD1).
- The NDA submission is being conducted under Breakthrough Therapy Designation and FDA-approved rolling review.
- Company expects to complete the submission in Q2 2026.
- Tinlarebant has shown transformative results in the Phase 3 DRAGON trial, potentially positioning it as the first approved therapy for STGD1.
- No financial results or updates on revenue, earnings, or cash runway were provided in this release.
Financial Impact
No material financial impact disclosed; development-stage update without revenue or earnings implications
Risk Factors
- FDA may not approve tinlarebant despite Breakthrough Therapy Designation.
- Clinical data may not translate into meaningful clinical benefit required for approval.
- Further dilution likely as company prepares for commercialization without current revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278392 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 6-K | $147.34 | awaiting T+20 | — | $147.33 (−0.01%) |
Sep 9, 2026 6w ago | Insider Cluster | $175.07 $152.52 | ▲ +12.88% | ▲ +15.01% | $147.33 (+15.85%) |
Aug 12, 2026 10w ago | 6-K | $166.28 $173.79 | ▲ +4.52% | ▲ +6.26% | $147.33 (−11.40%) |
Aug 12, 2026 10w ago | Press Release | $166.28 $173.79 | ▲ +4.52% | ▲ +6.26% | $147.33 (−11.40%) |
Jun 12, 2026 19w ago | 6-K | $144.24 $147.03 | ▲ +1.93% | ▲ +2.68% | $147.33 (+2.14%) |
May 20, 2026 22w ago | Press Release | $143.36 $146.12 | ▲ +1.93% | ▲ +1.18% | $147.33 (+2.77%) |
Apr 21, 2026 26w ago | 6-K | $167.42 $139.70 | ▼ −16.56% | ▼ −19.72% | $147.33 (−12.00%) |
Apr 21, 2026 26w ago | Press Release | $167.42 $139.70 | ▼ −16.56% | ▼ −19.72% | $147.33 (−12.00%) |
Apr 9, 2026 28w ago | Insider Cluster | $181.17 $156.21 | ▲ +13.78% | ▲ +21.34% | $147.33 (+18.68%) |
Apr 9, 2026 28w ago | Insider Cluster | $181.17 $156.21 | ▲ +13.78% | ▲ +21.34% | $147.33 (+18.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers